Updated recommendations on the use of ruxolitinib for the treatment of myelofibrosis

References

• Spivak JL. Myeloproliferative neoplasms. N Engl J Med. 2017;376(22):2168–2181.
   PubMed Web of Science ®Google Scholar
• Tefferi A. Primary myelofibrosis: 2021 update on diagnosis, risk-stratification and management. Am J Hematol. 2021;96(1):145–162.
   PubMed Web of Science ®Google Scholar
• Mesa RA. The evolving treatment paradigm in myelofibrosis. Leuk Lymphoma. 2013;54(2):242–251.
   PubMed Web of Science ®Google Scholar
• Breccia M, Baratè C, Benevolo G, et al. Tracing the decision-making process for myelofibrosis: diagnosis, stratification, and management of ruxolitinib therapy in real-word practice. Ann Hematol. 2020;99(1):65–72.
   PubMed Web of Science ®Google Scholar
• Cazzola M, Kralovics R. From Janus kinase 2 to calreticulin: the clinically relevant genomic landscape of myeloproliferative neoplasms. Blood. 2014;123(24):3714–3719.
   PubMed Web of Science ®Google Scholar
• Tefferi A, Lasho TL, Finke CM, et al. CALR vs JAK2 vs MPL-mutated or triple-negative myelofibrosis: clinical, cytogenetic and molecular comparisons. Leukemia. 2014;28(7):1472–1477.
   PubMed Web of Science ®Google Scholar
• Cervantes F, Dupriez B, Pereira A, et al. New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for myelofibrosis research and treatment. Blood. 2009;113(13):2895–2901.
   PubMed Web of Science ®Google Scholar
• Passamonti F, Cervantes F, Vannucchi AM, et al. A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for myeloproliferative neoplasms research and treatment). Blood. 2010;115(9):1703–1708.
   PubMed Web of Science ®Google Scholar
• Gangat N, Caramazza D, Vaidya R, et al. DIPSS plus: a refined dynamic international prognostic scoring system for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status. J Clin Oncol. 2011;29(4):392–397.
   PubMed Web of Science ®Google Scholar
• Tefferi A, Guglielmelli P, Nicolosi M, et al. GIPSS: genetically inspired prognostic scoring system for primary myelofibrosis. Leukemia. 2018;32(7):1631–1642.
   PubMed Web of Science ®Google Scholar
• Guglielmelli P, Lasho TL, Rotunno G, et al. MIPSS70: mutation-enhanced international prognostic score system for transplantation-age patients with primary myelofibrosis. J Clin Oncol. 2018;36(4):310–318.
   PubMed Web of Science ®Google Scholar
• Tefferi A, Guglielmelli P, Lasho TL, et al. MIPSS70+ version 2.0: mutation and karyotype-enhanced international prognostic scoring system for primary myelofibrosis. J Clin Oncol. 2018;36(17):1769–1770.
   PubMed Web of Science ®Google Scholar
• Farhadfar N, Cerquozzi S, Patnaik M, et al. Allogeneic hematopoietic stem-cell transplantation for myelofibrosis: a practical review. J Oncol Pract. 2016;12(7):611–621.
   PubMed Web of Science ®Google Scholar
• Bryan JC, Verstovsek S. Overcoming treatment challenges in myelofibrosis and polycythemia vera: the role of ruxolitinib. Cancer Chemother Pharmacol. 2016;77(6):1125–1142.
   PubMed Web of Science ®Google Scholar
• Devos T, Selleslag D, Zachée P, et al. Recommendations on the use of ruxolitinib for the treatment of myelofibrosis. Hematology. 2018;23(4):194–200.
   PubMed Web of Science ®Google Scholar
• Harrison C, Kiladjian JJ, Al-Ali HK, et al. JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. N Engl J Med. 2012;366(9):787–798.
   PubMed Web of Science ®Google Scholar
• Verstovsek S, Mesa RA, Gotlib J, et al. A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. N Engl J Med. 2012;366(9):799–807.
   PubMed Web of Science ®Google Scholar
• Harrison CN, Vannucchi AM, Kiladjian JJ, et al. Long-term findings from COMFORT-II, a phase 3 study of ruxolitinib vs best available therapy for myelofibrosis. Leukemia. 2016;30(8):1701–1707.
   PubMed Web of Science ®Google Scholar
• Verstovsek S, Mesa RA, Gotlib J, et al. Long-term treatment with ruxolitinib for patients with myelofibrosis: 5-year update from the randomized, double-blind, placebo-controlled, phase 3 COMFORT-I trial. J Hematol Oncol. 2017;10(1):55.
   PubMedGoogle Scholar
• Mead AJ, Milojkovic D, Knapper S, et al. Response to ruxolitinib in patients with intermediate-1-, intermediate-2-, and high-risk myelofibrosis: results of the UK ROBUST trial. Br J Haematol. 2015;170(1):29–39.
   PubMed Web of Science ®Google Scholar
• Al-Ali HK, Griesshammer M, Foltz L, et al. Primary analysis of JUMP, a phase 3b, expanded-access study evaluating the safety and efficacy of ruxolitinib in patients with myelofibrosis, including those with low platelet counts. Br J Haematol. 2020;189(5):888–903.
   PubMed Web of Science ®Google Scholar
• Al-Ali HK, Griesshammer M, le Coutre P, et al. Safety and efficacy of ruxolitinib in an open-label, multicenter, single-arm phase 3b expanded-access study in patients with myelofibrosis: a snapshot of 1144 patients in the JUMP trial. Haematologica. 2016;101(9):1065–1073.
   PubMed Web of Science ®Google Scholar
• Gupta V, Griesshammer M, Martino B, et al. Analysis of predictors of response to ruxolitinib in patients with myelofibrosis in the phase 3b expanded-access JUMP study. Leuk Lymphoma. 2021;62(4):918–926.
   PubMed Web of Science ®Google Scholar
• Palandri F, Palumbo GA, Bonifacio M, et al. Baseline factors associated with response to ruxolitinib: an independent study on 408 patients with myelofibrosis. Oncotarget. 2017;8(45):79073–79086.
   PubMedGoogle Scholar
• Maze D, Arcasoy MO, Henrie R, et al. Role of allogeneic hematopoietic cell transplant in patients with myelofibrosis in the JAK inhibitor era. 62nd American Society of Hematology (ASH) Meeting and Exposition, December 5-8, 2020. [cited October 22, 2021]. Available from: https://ash.confex.com/ash/2020/webprogram/Paper141790.html
   Google Scholar
• Lancman G, Mascarenhas J. Should we be treating lower risk myelofibrosis patients with a JAK2 inhibitor? Expert Rev Hematol. 2017;10(1):23–28.
   PubMed Web of Science ®Google Scholar
• Palandri F, Sabattini E, Maffioli M. Treating early-stage myelofibrosis. Ann Hematol. 2019;98(2):241–253.
   PubMed Web of Science ®Google Scholar
• Institut National d'Assurance Maladie-Invalidité (INAMI). Spécialités pharmaceutiques - Liste – Chapter IV - 01/10/2021 - Lijst - Farmaceutische specialiteiten. [cited October 26, 2021]. Available from: https://www.inami.fgov.be/fr/themes/cout-remboursement/par-mutualite/medicament-produits-sante/remboursement/specialites/Pages/specialites-pharma-liste-chap4.aspx
   Google Scholar
• Gerds AT, Gotlib J, Ali H, et al. NCCN guidelines version 1.2021. Myeloproliferative neoplasms. [cited May 7, 2021] Available from: https://www.nccn.org/guidelines/recently-published-guidelines
   Google Scholar
• Gupta V, Kosiorek HE, Mead A, et al. Ruxolitinib therapy followed by reduced-intensity conditioning for hematopoietic cell transplantation for myelofibrosis: myeloproliferative disorders research consortium 114 study. Biol Blood Marrow Transplant. 2019;25(2):256–264.
   PubMed Web of Science ®Google Scholar
• Zhang L, Yang F, Feng S. Allogeneic hematopoietic stem-cell transplantation for myelofibrosis. Ther Adv Hematol. 2020;11:204062072090600.
   Web of Science ®Google Scholar
• Robin M, Porcher R, Orvain C, et al. Ruxolitinib before allogeneic hematopoietic transplantation in patients with myelofibrosis on behalf SFGM-TC and FIM groups. Bone Marrow Transplant. 2021;Online ahead of print.
   Google Scholar
• Kröger NM, Deeg JH, Olavarria E, et al. Indication and management of allogeneic stem cell transplantation in primary myelofibrosis: a consensus process by an EBMT/ELN international working group. Leukemia. 2015;29(11):2126–2133.
   PubMed Web of Science ®Google Scholar
• Jain T, Mesa RA, Palmer JM. Allogeneic stem cell transplantation in myelofibrosis. Biol Blood Marrow Transplant. 2017;23(9):1429–1436.
   PubMed Web of Science ®Google Scholar
• European Medicines Agency. Jakavi: EPAR - product information. [Updated on September 14, 2021; cited October 25, 2021]. Available from: https://www.ema.europa.eu/en/documents/product-information/jakavi-epar-product-information_en.pdf
   Google Scholar
• Maschmeyer G, De Greef J, Mellinghoff SC, et al. Infections associated with immunotherapeutic and molecular targeted agents in hematology and oncology. A position paper by the European Conference on Infections in Leukemia (ECIL). Leukemia. 2019;33(4):844–862.
   PubMed Web of Science ®Google Scholar
• Barbui T, Thiele J, Gisslinger H, et al. The 2016 WHO classification and diagnostic criteria for myeloproliferative neoplasms: document summary and in-depth discussion. Blood Cancer J. 2018;8(2):15.
   PubMedGoogle Scholar
• Gupta V, Harrison C, Hexner EO, et al. The impact of anemia on overall survival in patients with myelofibrosis treated with ruxolitinib in the COMFORT studies. Haematologica. 2016;101(12):e482–e484.
   PubMed Web of Science ®Google Scholar
• Cervantes F, Ross DM, Radinoff A, et al. Efficacy and safety of a novel dosing strategy for ruxolitinib in the treatment of patients with myelofibrosis and anemia: the REALISE phase 2 study. Leukemia. 2021; Online ahead of print.
   Google Scholar
• McMullin MF, Harrison CN, Niederwieser D, et al. The use of erythropoiesis-stimulating agents with ruxolitinib in patients with myelofibrosis in COMFORT-II: an open-label, phase 3 study assessing efficacy and safety of ruxolitinib versus best available therapy in the treatment of myelofibrosis. Exp Hematol Oncol. 2015;4:26.
   PubMed Web of Science ®Google Scholar
• Crisà E, Cilloni D, Elli EM, et al. The use of erythropoiesis-stimulating agents is safe and effective in the management of anaemia in myelofibrosis patients treated with ruxolitinib. Br J Haematol. 2018;182(5):701–704.
   PubMed Web of Science ®Google Scholar
• Huang J, Tefferi A. Erythropoiesis stimulating agents have limited therapeutic activity in transfusion-dependent patients with primary myelofibrosis regardless of serum erythropoietin level. Eur J Haematol. 2009;83(2):154–155.
   PubMed Web of Science ®Google Scholar
• Fenaux P, Kiladjian JJ, Platzbecker U. Luspatercept for the treatment of anemia in myelodysplastic syndromes and primary myelofibrosis. Blood. 2019;133(8):790–794.
   PubMed Web of Science ®Google Scholar
• Gerds AT, Vannucchi AM, Passamonti F, et al. Duration of response to luspatercept in patients (Pts) requiring red blood cell (RBC) transfusions with myelofibrosis (MF) - updated data from the phase 2 ACE-536-MF-001 study. Blood. 2020;136(Suppl. 1):47–48.
   Google Scholar
• Masarova L, Alhuraiji A, Bose P, et al. Significance of thrombocytopenia in patients with primary and postessential thrombocythemia/polycythemia vera myelofibrosis. Eur J Haematol. 2018;100(3):257–263.
   PubMed Web of Science ®Google Scholar
• Mesa RA, Cortes J. Optimizing management of ruxolitinib in patients with myelofibrosis: the need for individualized dosing. J Hematol Oncol. 2013;6:79.
   PubMed Web of Science ®Google Scholar
• Heine A, Brossart P, Wolf D. Ruxolitinib is a potent immunosuppressive compound: is it time for anti-infective prophylaxis? Blood. 2013;122(23):3843–3844.
   PubMed Web of Science ®Google Scholar
• European Medicines Agency. Zostavax: EPAR - product information. [updated on July 29, 2021; cited October 22, 2021]. Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/zostavax
   Google Scholar
• European Medicines Agency. Shingrix: EPAR - product information. [updated on October 13, 2021; cited October 22, 2021]. Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/shingrix
   Google Scholar
• Hoge Gezondheidsraad (HGR). Vaccinatie tegen herpes zoster (zona): herzien advies van de Hoge Gezondheidsraad (HGR). Folia. April 2018;45(04):6–7. [cited October 22, 2021] Available from: https://www.bcfi.be/folia_pdfs/NL/P45N04D.pdf
   Google Scholar
• Krauth MT, Burgstaller S, Buxhofer-Ausch V, et al. Ruxolitinib therapy for myelofibrosis in Austria: consensus on therapy management. Wien Klin Wochenschr. 2018;130(17-18):495–504.
   PubMed Web of Science ®Google Scholar
• Porpaczy E, Tripolt S, Hoelbl-Kovacic A, et al. Aggressive B-cell lymphomas in patients with myelofibrosis receiving JAK1/2 inhibitor therapy. Blood. 2018;132(7):694–706.
   PubMed Web of Science ®Google Scholar
• Tremblay D, King A, Li L, et al. Risk factors for infections and secondary malignancies in patients with a myeloproliferative neoplasm treated with ruxolitinib: a dual-center, propensity score-matched analysis. Leuk Lymphoma. 2020;61(3):660–667.
   PubMed Web of Science ®Google Scholar
• Barraco F, Greil R, Herbrecht R, et al. Real-world non-interventional long-term post-authorisation safety study of ruxolitinib in myelofibrosis. Br J Haematol. 2020;191(5):764–774.
   PubMed Web of Science ®Google Scholar
• Barbui T, Ghirardi A, Masciulli A, et al. Second cancer in Philadelphia negative myeloproliferative neoplasms (MPN-K). A nested case-control study. Leukemia. 2019;33(8):1996–2005.
   PubMed Web of Science ®Google Scholar
• Polverelli N, Elli EM, Abruzzese E, et al. Second primary malignancy in myelofibrosis patients treated with ruxolitinib. Br J Haematol. 2021;193(2):356–368.
   PubMed Web of Science ®Google Scholar
• Gupta V, Cerquozzi S, Foltz L, et al. Patterns of ruxolitinib therapy failure and its management in myelofibrosis: perspectives of the Canadian Myeloproliferative Neoplasm Group. JCO Oncol Pract. 2020;16(7):351–359.
   PubMedGoogle Scholar
• Pemmaraju N, Kantarjian H, Nastoupil L, et al. Characteristics of patients with myeloproliferative neoplasms with lymphoma, with or without JAK inhibitor therapy. Blood. 2019;133(21):2348–2351.
   PubMed Web of Science ®Google Scholar
• Pardanani A, Tefferi A. Definition and management of ruxolitinib treatment failure in myelofibrosis. Blood Cancer J. 2014;4(12):e268.
   PubMedGoogle Scholar
• Harrison CN, Schaap N, Mesa RA. Management of myelofibrosis after ruxolitinib failure. Ann Hematol. 2020;99(6):1177–1191.
   PubMed Web of Science ®Google Scholar
• Coltro G, Rotunno G, Mannelli L, et al. RAS/CBL mutations predict resistance to JAK inhibitors in myelofibrosis and are associated with poor prognostic features. Blood Adv. 2020;4(15):3677–3687.
   PubMed Web of Science ®Google Scholar
• Patel KP, Newberry KJ, Luthra R, et al. Correlation of mutation profile and response in patients with myelofibrosis treated with ruxolitinib. Blood. 2015;126(6):790–797.
   PubMed Web of Science ®Google Scholar
• Miller CB, Komrokji RS, Mesa RA, et al. Practical measures of clinical benefit with ruxolitinib therapy: an exploratory analysis of COMFORT-I. Clin Lymphoma Myeloma Leuk. 2017;17(8):479–487.
   PubMed Web of Science ®Google Scholar
• Emanuel RM, Dueck AC, Geyer HL, et al. Myeloproliferative neoplasm (MPN) symptom assessment form total symptom score: prospective international assessment of an abbreviated symptom burden scoring system among patients with MPNs. J Clin Oncol. 2012;30(33):4098–4103.
   PubMed Web of Science ®Google Scholar
• Palandri F, Palumbo GA, Elli EM, et al. Ruxolitinib discontinuation syndrome: incidence, risk factors, and management in 251 patients with myelofibrosis. Blood Cancer J. 2021;11(1):4.
   PubMed Web of Science ®Google Scholar
• Palandri F, Tiribelli M, Breccia M, et al. Ruxolitinib rechallenge in resistant or intolerant patients with myelofibrosis: frequency, therapeutic effects, and impact on outcome. Cancer. 2021;127(15):2657–2665.
   PubMed Web of Science ®Google Scholar